Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Breast Cancer

  Free Subscription


1 AJR Am J Roentgenol
1 Am J Pathol
1 Am J Surg
1 Ann Oncol
2 Ann Surg
2 Ann Surg Oncol
4 BMC Cancer
3 Br J Cancer
3 Breast Cancer
6 Breast Cancer Res
15 Breast Cancer Res Treat
3 Breast J
1 Cancer
3 Cancer Lett
4 Cancer Res
2 Clin Breast Cancer
3 Clin Cancer Res
1 Curr Treat Options Oncol
1 Eur J Cancer
2 Eur J Surg Oncol
1 Gene
3 Histopathology
3 Int J Cancer
2 Int J Radiat Oncol Biol Phys
1 J Biol Chem
1 J Clin Invest
4 J Clin Oncol
1 J Surg Oncol
1 Mod Pathol
4 N Engl J Med
1 Nat Rev Clin Oncol
3 NPJ Breast Cancer
5 Oncogene
3 Oncol Rep
1 Pathology
9 PLoS One
1 Proc Natl Acad Sci U S A
1 Science
1 Semin Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. LEE CH, Bryce Y, Zheng J, Sung JS, et al
    Outcome of Screening MRI in Premenopausal Women as a Function of the Week of the Menstrual Cycle.
    AJR Am J Roentgenol. 2020 Mar 11:1-7. doi: 10.2214/AJR.18.19960.
    PubMed         Abstract available

    Am J Pathol

  2. RASMUSSON A, Zilenaite D, Nestarenkaite A, Augulis R, et al
    Immunogradient Indicators for Antitumor Response Assessment by Automated Tumor-Stroma Interface Zone Detection.
    Am J Pathol. 2020;190:1309-1322.
    PubMed         Abstract available

    Am J Surg

  3. THEISS LM, Chu DI
    Invited commentary on "Delving deeper into disparity: The impact of health literacy on the surgical care of breast cancer patients".
    Am J Surg. 2020 Jun 11. pii: S0002-9610(20)30361.

    Ann Oncol

  4. LYMAN GH, Kuderer NM
    Personalized cancer supportive care in COVID-19 era.
    Ann Oncol. 2020;31:835-837.

    Ann Surg

  5. LAI HW, Toesca A, Sarfati B, Park HS, et al
    Consensus Statement on Robotic Mastectomy-Expert Panel From International Endoscopic and Robotic Breast Surgery Symposium (IERBS) 2019.
    Ann Surg. 2020;271:1005-1012.
    PubMed         Abstract available

  6. OFFODILE AC 2ND, Hwang ES, Greenup RA
    Contralateral Prophylactic Mastectomy in the Era of Financial Toxicity: An Additional Point for Concern?
    Ann Surg. 2020;271:817-818.

    Ann Surg Oncol

  7. OKUNO J, Miyake T, Sota Y, Tanei T, et al
    Development of Prediction Model Including MicroRNA Expression for Sentinel Lymph Node Metastasis in ER-Positive and HER2-Negative Breast Cancer.
    Ann Surg Oncol. 2020 Jun 24. pii: 10.1245/s10434-020-08735.
    PubMed         Abstract available

  8. CHANG YT, Shih SL, Loh EW, Tam KW, et al
    Effects of Fibrin Sealant on Seroma Reduction for Patients with Breast Cancer Undergoing Axillary Dissection: Meta-Analysis of Randomized Controlled Trials.
    Ann Surg Oncol. 2020 Jun 20. pii: 10.1245/s10434-020-08747.
    PubMed         Abstract available

    BMC Cancer

  9. ZHANG Y, Yu C
    Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer.
    BMC Cancer. 2020;20:575.
    PubMed         Abstract available

  10. FENG Q, Hu Q, Liu Y, Yang T, et al
    Diagnosis of triple negative breast cancer based on radiomics signatures extracted from preoperative contrast-enhanced chest computed tomography.
    BMC Cancer. 2020;20:579.
    PubMed         Abstract available

  11. SONG Y, Zhao B, Xu Y, Ren X, et al
    Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer.
    BMC Cancer. 2020;20:584.
    PubMed         Abstract available

  12. SIZEMORE G, McLaughlin S, Newman M, Brundage K, et al
    Opening large-conductance potassium channels selectively induced cell death of triple-negative breast cancer.
    BMC Cancer. 2020;20:595.
    PubMed         Abstract available

    Br J Cancer

  13. MING C, Viassolo V, Probst-Hensch N, Dinov ID, et al
    Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations.
    Br J Cancer. 2020 Jun 22. pii: 10.1038/s41416-020-0937.
    PubMed         Abstract available

  14. PARK SA, Sung NJ, Choi BJ, Kim W, et al
    Gremlin-1 augments the oestrogen-related receptor alpha signalling through EGFR activation: implications for the progression of breast cancer.
    Br J Cancer. 2020 Jun 23. pii: 10.1038/s41416-020-0945.
    PubMed         Abstract available

  15. MESA-EGUIAGARAY I, Wild SH, Rosenberg PS, Bird SM, et al
    Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data.
    Br J Cancer. 2020 Jun 19. pii: 10.1038/s41416-020-0938.
    PubMed         Abstract available

    Breast Cancer

  16. MALIK SS, Zia A, Rashid S, Mubarik S, et al
    XPC as breast cancer susceptibility gene: evidence from genetic profiling, statistical inferences and protein structural analysis.
    Breast Cancer. 2020 Jun 19. pii: 10.1007/s12282-020-01121.
    PubMed         Abstract available

  17. KAJIHARA N, Kitagawa F, Kobayashi T, Wada H, et al
    Interleukin-34 contributes to poor prognosis in triple-negative breast cancer.
    Breast Cancer. 2020 Jun 23. pii: 10.1007/s12282-020-01123.
    PubMed         Abstract available

  18. BARTOLO A, Neves M, Carvalho B, Reis S, et al
    Fertility under uncertainty: exploring differences in fertility-related concerns and psychosocial aspects between breast cancer survivors and non-cancer infertile women.
    Breast Cancer. 2020 Jun 24. pii: 10.1007/s12282-020-01124.
    PubMed         Abstract available

    Breast Cancer Res

  19. ROBERTS MS, Anstine LJ, Finke VS, Bryson BL, et al
    KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Breast Cancer Res. 2020;22:66.
    PubMed         Abstract available

  20. FINLAY-SCHULTZ J, Jacobsen BM, Riley D, Paul KV, et al
    New generation breast cancer cell lines developed from patient-derived xenografts.
    Breast Cancer Res. 2020;22:68.
    PubMed         Abstract available

  21. GUO H, Ding Q, Gong Y, Gilcrease MZ, et al
    Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
    Breast Cancer Res. 2020;22:69.
    PubMed         Abstract available

  22. BERGQVIST M, Elebro K, Sandsveden M, Borgquist S, et al
    Effects of tumor-specific CAP1 expression and body constitution on clinical outcomes in patients with early breast cancer.
    Breast Cancer Res. 2020;22:67.
    PubMed         Abstract available

  23. MALINIAK ML, Cheriyan AM, Sherman ME, Liu Y, et al
    Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer.
    Breast Cancer Res. 2020;22:65.
    PubMed         Abstract available

  24. BLOHMER M, Zhu L, Atkinson JM, Beriwal S, et al
    Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology.
    Breast Cancer Res. 2020;22:70.
    PubMed         Abstract available

    Breast Cancer Res Treat

  25. CHAMBERLIN MD, Wells JD, Shee K, Bean JR, et al
    Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05714.
    PubMed         Abstract available

  26. XU B, Li W, Zhang Q, Shao Z, et al
    Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
    Breast Cancer Res Treat. 2020 Jun 20. pii: 10.1007/s10549-020-05728.
    PubMed         Abstract available

  27. HORIMOTO Y, Sasahara N, Sasaki R, Hlaing MT, et al
    High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05751.
    PubMed         Abstract available

  28. HARBORG S, Heide-Jorgensen U, Ahern TP, Ewertz M, et al
    Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
    Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05749.
    PubMed         Abstract available

  29. ROBERTSON S, Acs B, Lippert M, Hartman J, et al
    Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
    Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05752.
    PubMed         Abstract available

  30. WEI Y, Wang X, Zhang Z, Zhao C, et al
    Impact of NR5A2 and RYR2 3'UTR polymorphisms on the risk of breast cancer in a Chinese Han population.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05736.
    PubMed         Abstract available

  31. VERMA R, Hanby AM, Horgan K, Verghese ET, et al
    Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05757.
    PubMed         Abstract available

  32. CHENG AS, Leung SCY, Gao D, Burugu S, et al
    Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    Breast Cancer Res Treat. 2020 Jun 20. pii: 10.1007/s10549-020-05745.
    PubMed         Abstract available

  33. STARKINGS R, Shilling V, Jenkins V, Fallowfield L, et al
    A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05741.
    PubMed         Abstract available

  34. HOWLADER NR, Rahman MM, Hossain MA, Sultana R, et al
    Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population.
    Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05738.
    PubMed         Abstract available

  35. KAR A, Koto K, Walker D, Trudeau T, et al
    ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR(+)HER2(+) breast cancer patients.
    Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05734.
    PubMed         Abstract available

  36. BESIC N, Smrekar J, Strazisar B
    Chronic adverse effects after an axillary lymphadenectomy in breast cancer patients after administering weaker and stronger postoperative analgesia: results of a prospective double-blind randomized study.
    Breast Cancer Res Treat. 2020 Jun 18. pii: 10.1007/s10549-020-05713.
    PubMed         Abstract available

  37. OBENG-GYASI S, Oppong B, Paskett ED, Lustberg M, et al
    Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?
    Breast Cancer Res Treat. 2020 Jun 16. pii: 10.1007/s10549-020-05740.
    PubMed         Abstract available

  38. STASZEWSKY L, Robusto F, Lepore V, Bisceglia L, et al
    Cardiovascular mortality and morbidity burden in successive and age pre-stratified case-control cohorts of breast cancer women. A population-based study.
    Breast Cancer Res Treat. 2020 Jun 25. pii: 10.1007/s10549-020-05758.
    PubMed         Abstract available

  39. HAM A, Kim MH, Kim GM, Kim JH, et al
    Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05750.
    PubMed         Abstract available

    Breast J

  40. KIM E, Park B, Lee W, Min J, et al
    Metastatic breast cancer presented as great toenail pyogenic granuloma.
    Breast J. 2020 Jun 24. doi: 10.1111/tbj.13903.

  41. PURI A, Reddy TP, Patel TA, Chang JC, et al
    Metastatic triple-negative breast cancer: Established and emerging treatments.
    Breast J. 2020 Jun 23. doi: 10.1111/tbj.13946.
    PubMed         Abstract available

    Overall survival and related prognostic factors for familial breast cancer patients: A single institution study in Iran.
    Breast J. 2020 Jun 21. doi: 10.1111/tbj.13942.


  43. SUAREZ-ALMAZOR ME, Herrera R, Lei X, Chavez-MacGregor M, et al
    Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab.
    Cancer. 2020 Jun 23. doi: 10.1002/cncr.33035.
    PubMed         Abstract available

    Cancer Lett

  44. BABAK MV, Zalutsky MR, Balyasnikova IV
    Heterogeneity and vascular permeability of breast cancer brain metastases.
    Cancer Lett. 2020 Jun 16. pii: S0304-3835(20)30342.
    PubMed         Abstract available

  45. HUANG B, Yip WK, Wei N, Luo KQ, et al
    Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells.
    Cancer Lett. 2020 Jun 22. pii: S0304-3835(20)30340.
    PubMed         Abstract available

  46. AGGARWAL V, Miranda O, Johnston PA, Sant S, et al
    Three dimensional engineered models to study hypoxia biology in breast cancer.
    Cancer Lett. 2020 Jun 19. pii: S0304-3835(20)30292.
    PubMed         Abstract available

    Cancer Res

  47. SAXENA M, Kalathur RKR, Rubinstein N, Vettiger A, et al
    A Pygopus 2-histone interaction is critical for cancer cell de-differentiation and progression in malignant breast cancer.
    Cancer Res. 2020 Jun 25. pii: 0008-5472.CAN-19-2910.
    PubMed         Abstract available

  48. GEORGESS D, Padmanaban V, Sirka OK, Coutinho K, et al
    Twist1-Induced Epithelial Dissemination Requires Prkd1 Signaling.
    Cancer Res. 2020;80:204-218.
    PubMed         Abstract available

  49. FLETCHER A, Read ML, Thornton CEM, Larner DP, et al
    Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.
    Cancer Res. 2020;80:102-115.
    PubMed         Abstract available

  50. LOH XY, Sun QY, Ding LW, Mayakonda A, et al
    RNA-Binding Protein ZFP36L1 Suppresses Hypoxia and Cell-Cycle Signaling.
    Cancer Res. 2020;80:219-233.
    PubMed         Abstract available

    Clin Breast Cancer

  51. FABI A, Mottolese M, Di Benedetto A, Sperati F, et al
    p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.
    Clin Breast Cancer. 2020 May 13. pii: S1526-8209(20)30107.
    PubMed         Abstract available

  52. LV M, Mao Y, Song Y, Wang Y, et al
    Clinical Features and Survival of Single Hormone Receptor-Positive Breast Cancer: A Population-Based Study of 531,605 Patients.
    Clin Breast Cancer. 2020 Apr 24. pii: S1526-8209(20)30088.
    PubMed         Abstract available

    Clin Cancer Res

  53. MAGBANUA MJM, Savenkov O, Asmus EJ, Ballman K, et al
    Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab.
    Clin Cancer Res. 2020 Jun 25. pii: 1078-0432.CCR-20-1329.
    PubMed         Abstract available

  54. VIDULA N, Dubash TD, Lawrence MS, Simoneau A, et al
    Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer.
    Clin Cancer Res. 2020 Jun 22. pii: 1078-0432.CCR-20-0638.
    PubMed         Abstract available

  55. SESTAK I, Filipits M, Buus R, Rudas M, et al
    Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-20-0260.
    PubMed         Abstract available


  56. YAFFE MJ
    Revamp governance of Canadian Task Force on Preventive Health Care.
    CMAJ. 2020;192:E145.

  57. KLARENBACH SW, Moore AE, Thombs BD
    The authors respond to: "Revamp governance of Canadian Task Force on Preventive Health Care".
    CMAJ. 2020;192:E146-E147.

    Curr Treat Options Oncol

  58. BARROSO-SOUSA R, Tolaney SM
    Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
    Curr Treat Options Oncol. 2020;21:59.
    PubMed         Abstract available

    Eur J Cancer

  59. STEENBRUGGEN TG, van Werkhoven E, van Ramshorst MS, Dezentje VO, et al
    Adjuvant chemotherapy in small node-negative triple-negative breast cancer.
    Eur J Cancer. 2020;135:66-74.
    PubMed         Abstract available

    Eur J Surg Oncol

  60. GHIDINELLI F, Bianchi A
    COVID-19 and breast cancer: Impact on patients and breast care centers.
    Eur J Surg Oncol. 2020 Jun 17. pii: S0748-7983(20)30550.

  61. MARTA GN
    Radiation therapy after nipple-sparing and skin-sparing mastectomies for early-stage breast cancer patients: Too many uncertainties in clinical practice.
    Eur J Surg Oncol. 2020 Jun 14. pii: S0748-7983(20)30527.


  62. JAMALZEI B, Karami Tehrani FS, Atri M
    Evaluation of LDL receptor and Scavenger Receptor, Class B, Type 1 in the malignant and benign breast tumors: The correlation with the expression of miR-199a-5p, miR-199b-5p and miR-455-5p.
    Gene. 2020;749:144720.
    PubMed         Abstract available


  63. HIDA AI, Omanovic D, Pedersen L, Oshiro Y, et al
    Automated assessment of Ki-67 in breast cancer: the utility of digital image analysis using virtual triple staining and whole slide imaging.
    Histopathology. 2020 Jun 24. doi: 10.1111/his.14140.
    PubMed         Abstract available

  64. SHOLL LM
    Programmed death ligand 1 immunohistochemistry: can we agree on this?
    Histopathology. 2020;76:189-190.

  65. VAN STEENHOVEN JEC, Kuijer A, Kornegoor R, van Leeuwen AM, et al
    Assessment of Tumour Proliferation by Mitotic Activity Index, Ki67 and Phosphohistone H3 in Early stage Luminal Breast Cancer.
    Histopathology. 2020 Jun 17. doi: 10.1111/his.14185.
    PubMed         Abstract available

    Int J Cancer

  66. CHEN Y, Guan Y, Wang J, Ma F, et al
    Platinum-based chemotherapy in advanced triple-negative breast cancer: a multicenter real-world study in China.
    Int J Cancer. 2020 Jun 25. doi: 10.1002/ijc.33175.
    PubMed         Abstract available

  67. TOSS A, Lambertini M, Punie K, Grandi G, et al
    Int J Cancer. 2020 Jun 17. doi: 10.1002/ijc.33160.

  68. WANG T, Bradshaw PT, Moorman PG, Nyante SJ, et al
    Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project.
    Int J Cancer. 2020 Jun 25. doi: 10.1002/ijc.33174.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  69. NIMALASENA S, Gothard L, Anbalagan S, Allen S, et al
    Intratumoural hydrogen peroxide with radiotherapy in locally advanced breast cancer: results from a Phase I clinical trial.
    Int J Radiat Oncol Biol Phys. 2020 Jun 22. pii: S0360-3016(20)31309.
    PubMed         Abstract available

  70. HUANG Z, Zhu L, Huang XB, Tang Y, et al
    Postmastectomy radiotherapy based on pathological nodal status in clinical node-positive stage II-III breast cancer treated with neoadjuvant chemotherapy.
    Int J Radiat Oncol Biol Phys. 2020 Jun 22. pii: S0360-3016(20)31315.
    PubMed         Abstract available

    J Biol Chem

  71. SEACHRIST DD, Hannigan MM, Ingles NN, Webb BM, et al
    --The transcriptional repressor BCL11A promotes breast cancer metastasis.
    J Biol Chem. 2020 Jun 23. pii: RA120.014018. doi: 10.1074/jbc.RA120.014018.
    PubMed         Abstract available

    J Clin Invest

  72. GARCIA-RECIO S, Thennavan A, East MP, Parker JS, et al
    FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
    J Clin Invest. 2020 Jun 23. pii: 130323. doi: 10.1172/JCI130323.
    PubMed         Abstract available

    J Clin Oncol

  73. KATZ A
    Is It Appropriate to Use the Result of an Unplanned, Exploratory, Nonstatistically Significant Subgroup Analysis to Support a Treatment Recommendation in an ASCO Treatment Guideline?
    J Clin Oncol. 2020;38:102.

  74. HENRY NL, Andre F, Ismaila N, Somerfield MR, et al
    Reply to A. Katz.
    J Clin Oncol. 2020;38:102-103.

  75. GEIERSBACH KB, Meyer RG, Sill DR, Mounajjed T, et al
    Working Up Group 4 Equivocal HER2 Samples Tested by Fluorescence in Situ Hybridization in a Reference Laboratory Setting: Past, Present, and Future.
    J Clin Oncol. 2020;38:175-176.

  76. PISTILLI B, Paci A, Ferreira AR, Di Meglio A, et al
    Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.
    J Clin Oncol. 2020 Jun 22:JCO1901758. doi: 10.1200/JCO.19.01758.
    PubMed         Abstract available

    J Surg Oncol

  77. KOPKASH K, Sisco M, Poli E, Seth A, et al
    The modern approach to the nipple-sparing mastectomy.
    J Surg Oncol. 2020;122:29-35.
    PubMed         Abstract available

    Mod Pathol

  78. CHRISTGEN M, Bartels S, van Luttikhuizen JL, Bublitz J, et al
    E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements.
    Mod Pathol. 2020 Jun 22. pii: 10.1038/s41379-020-0591.
    PubMed         Abstract available

    N Engl J Med

  79. SCHMID P, Dent R, O'Shaughnessy J
    Pembrolizumab for Early Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2020;382:e108.

  80. CETIN B, Gumusay O
    Pembrolizumab for Early Triple-Negative Breast Cancer.
    N Engl J Med. 2020;382:e108.

  81. WINER EP
    Therapy for HER2-Positive Metastatic Breast Cancer. Reply.
    N Engl J Med. 2020;382:e98.

    Therapy for HER2-Positive Metastatic Breast Cancer.
    N Engl J Med. 2020;382:e98.

    Nat Rev Clin Oncol

  83. PASHAYAN N, Antoniou AC, Ivanus U, Esserman LJ, et al
    Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Nat Rev Clin Oncol. 2020 Jun 18. pii: 10.1038/s41571-020-0388.
    PubMed         Abstract available

    NPJ Breast Cancer

  84. BERGHOLTZ H, Lien TG, Swanson DM, Frigessi A, et al
    Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.
    NPJ Breast Cancer. 2020;6:26.
    PubMed         Abstract available

  85. SEHL ME, Carroll JE, Horvath S, Bower JE, et al
    The acute effects of adjuvant radiation and chemotherapy on peripheral blood epigenetic age in early stage breast cancer patients.
    NPJ Breast Cancer. 2020;6:23.
    PubMed         Abstract available

  86. ZENG Z, Vo A, Li X, Shidfar A, et al
    Somatic genetic aberrations in benign breast disease and the risk of subsequent breast cancer.
    NPJ Breast Cancer. 2020;6:24.
    PubMed         Abstract available


  87. SUNG JS, Kang CW, Kang S, Jang Y, et al
    ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts.
    Oncogene. 2020;39:664-676.
    PubMed         Abstract available

  88. SAVA GP, Fan H, Fisher RA, Lusvarghi S, et al
    ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942.
    Oncogene. 2020;39:651-663.
    PubMed         Abstract available

  89. DIAS MM, Adamoski D, Dos Reis LM, Ascencao CFR, et al
    GLS2 is protumorigenic in breast cancers.
    Oncogene. 2020;39:690-702.
    PubMed         Abstract available

  90. SUN T, Wu Z, Wang X, Wang Y, et al
    LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression.
    Oncogene. 2020 Jun 23. pii: 10.1038/s41388-020-1338.
    PubMed         Abstract available

  91. HRUSCHKA N, Kalisz M, Subijana M, Grana-Castro O, et al
    The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver.
    Oncogene. 2020 Jun 25. pii: 10.1038/s41388-020-1376.
    PubMed         Abstract available

    Oncol Rep

  92. SHI Y, Wang M, Wang P, Zhang T, et al
    Alisol A is potentially therapeutic in human breast cancer cells.
    Oncol Rep. 2020 Jun 22. doi: 10.3892/or.2020.7654.
    PubMed         Abstract available

  93. LI C, Li X, Li G, Sun L, et al
    Identification of a prognosisassociated signature associated with energy metabolism in triplenegative breast cancer.
    Oncol Rep. 2020 Jun 23. doi: 10.3892/or.2020.7657.
    PubMed         Abstract available

  94. ZHAO Y, Onda K, Sugiyama K, Yuan B, et al
    [Corrigendum] Antitumor effects of arsenic disulfide on the viability, migratory ability, apoptosis and autophagy of breast cancer cells.
    Oncol Rep. 2020 Jun 19. doi: 10.3892/or.2020.7653.
    PubMed         Abstract available


  95. FUCHS TL, Pearson A, Pickett J, Diakos C, et al
    Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases.
    Pathology. 2020 Jun 14. pii: S0031-3025(20)30822.
    PubMed         Abstract available

    PLoS One

  96. ARCHER S, Babb de Villiers C, Scheibl F, Carver T, et al
    Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study.
    PLoS One. 2020;15:e0229999.
    PubMed         Abstract available

  97. THIJSSEN B, Wessels LFA
    Approximating multivariate posterior distribution functions from Monte Carlo samples for sequential Bayesian inference.
    PLoS One. 2020;15:e0230101.
    PubMed         Abstract available

  98. NEWTON A, Predina J, Mison M, Runge J, et al
    Intraoperative near-infrared imaging can identify canine mammary tumors, a spontaneously occurring, large animal model of human breast cancer.
    PLoS One. 2020;15:e0234791.
    PubMed         Abstract available

  99. Retraction: Macrophage Colony-Stimulating Factor Augments Tie2-Expressing Monocyte Differentiation, Angiogenic Function, and Recruitment in a Mouse Model of Breast Cancer.
    PLoS One. 2020;15:e0235096.

  100. HAMY AS, Darrigues L, Laas E, De Croze D, et al
    Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
    PLoS One. 2020;15:e0234191.
    PubMed         Abstract available

  101. BURGUIN A, Furrer D, Ouellette G, Jacob S, et al
    Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
    PLoS One. 2020;15:e0234991.
    PubMed         Abstract available

  102. OKUMA H, Sudah M, Kettunen T, Niukkanen A, et al
    Peritumor to tumor apparent diffusion coefficient ratio is associated with biologically more aggressive breast cancer features and correlates with the prognostication tools.
    PLoS One. 2020;15:e0235278.
    PubMed         Abstract available

  103. DEMIRCIOGLU A, Grueneisen J, Ingenwerth M, Hoffmann O, et al
    A rapid volume of interest-based approach of radiomics analysis of breast MRI for tumor decoding and phenotyping of breast cancer.
    PLoS One. 2020;15:e0234871.
    PubMed         Abstract available

  104. RAISNER R, Bainer R, Haverty PM, Benedetti KL, et al
    Super-enhancer acquisition drives oncogene expression in triple negative breast cancer.
    PLoS One. 2020;15:e0235343.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  105. SCHNELL M, Mittal S, Falahkheirkhah K, Mittal A, et al
    All-digital histopathology by infrared-optical hybrid microscopy.
    Proc Natl Acad Sci U S A. 2020;117:3388-3396.
    PubMed         Abstract available


    COVID-19 and cancer.
    Science. 2020;368:1290.

    Semin Oncol

  107. MALHOTRA MK, Emens LA
    The evolving management of metastatic triple negative breast cancer.
    Semin Oncol. 2020 May 28. pii: S0093-7754(20)30044.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.